MyFinsight
Home
Blog
About
Contact
Proceeds from issuance of
common stock from...
$601,846K
Proceeds from issuance of
shares through...
$9,032K
Net cash provided by
financing activities
$601,583K
Canceled cashflow
$9,295K
Net increase
(decrease) in cash, cash...
$86,884K
Canceled cashflow
$514,699K
Taxes paid related to
the net share...
$9,295K
Accrued contract
manufacturing expenses
$54,852K
Stock-based compensation
expense
$37,964K
Depreciation and
amortization
$2,947K
Amortization of operating
lease right-of-use...
$2,907K
Unrealized foreign
exchange loss (gain)
-$2,201K
Maturities of investments
$340,631K
Sales of investments
$24,882K
Net cash used in
operating activities
-$280,625K
Net cash provided by
(used in) investing...
-$233,410K
Effect of exchange rate
changes on cash and cash...
-$664K
Canceled cashflow
$100,871K
Canceled cashflow
$365,513K
Net loss
-$320,622K
Purchases of investments
$584,129K
Other assets
$16,876K
Accrued expenses
-$15,571K
Accrued compensation
-$15,018K
Prepaid expenses and
other current assets
$8,743K
Net accretion of
discounts on investments
$3,112K
Operating lease
liabilities
-$1,285K
Accounts payable
-$269K
Purchases of
manufacturing facility...
$12,687K
Purchases of property and
equipment
$2,107K
Back
Back
Cash Flow
Vaxcyte, Inc. (PCVX)
Vaxcyte, Inc. (PCVX)
source: myfinsight.com